I'm LongbridgeAI, I can summarize articles.Ionis Pharma fell 6.68% this week to close at $54.21, lagging the S&P 500 by around 5.88 percentage points. It was a four-day week. The stock opened on Monday (Sep 8) with a gap lower, briefly rallied to an intraday high of $57.43, then drifted down over the next three sessions and finished near the week’s low at $54.21 on Friday (Sep 11). Average daily volume of 4.36m shares ran about 69% above the 60-day median.
The Week
Ionis Pharma fell 6.68% this week to close at $54.21, lagging the S&P 500 by around 5.88 percentage points. It was a four-day week. The stock opened on Monday (Sep 8) with a gap lower, briefly rallied to an intraday high of $57.43, then drifted down over the next three sessions and finished near the week’s low at $54.21 on Friday (Sep 11). Average daily volume of 4.36m shares ran about 69% above the 60-day median.
Key Events
The main story was partner Novartis’s heart drug pelacarsen missing its primary endpoint in a Phase 3 trial. On Tuesday (Sep 8), the news hit pre-market and Ionis fell more than 7% intraday, dragging peers such as Novartis and Royalty Pharma lower. Yet Canaccord Genuity reiterated its buy rating on the same day, arguing the Lp(a) HORIZON setback had limited impact and keeping a $100 target. Over the next two days the focus shifted to broader implications for the emerging heart medicine class, while Ionis itself had no further product-level blow-ups.
Analyst Ratings
Coverage totals 24 brokers: 10 rate buy, 9 overweight, 5 hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target of $84.23 sits about 55.4% above the current price. The target range runs from $54 to $105, a wide spread that signals real disagreement; the low end sits near spot, reflecting cautious expectations after the trial miss. Ionis ranks 14th within its industry group of 506 names.
The Week Ahead
Next week brings the New York Fed manufacturing index on Tuesday (Sep 15), followed on Wednesday (Sep 16) by a dense run of US data: retail sales, retail sales ex-autos, retail control, and the NAHB housing market index. These macro prints have limited direct relevance to Ionis fundamentals, but they can shift risk appetite across biotech. Meanwhile, the fallout from the pelacarsen failure is still being digested, and further commentary on the heart drug class could keep sector sentiment choppy.
In Short
The signals are split. Brokers still hold a buy consensus with a target roughly 55% above spot, which is the constructive side. But the stock has pulled back sharply from its July high of $86.74, and the latest session’s large-lot flow turned net seller. Next week’s macro data and the biotech sector’s digestion of the pelacarsen news will test whether the $54 area can hold.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.